Almost four years after CVS Health Corp. spent nearly $13 billion to acquire Omnicare, the long-term-care (LTC) pharmacy business attracted negative attention as a major contributor to “headwinds” in the company’s Feb. 20 report on fourth quarter and full-year 2018 financial results. “We certainly expected Omnicare performance to stabilize and improve,” CVS Health President and CEO Larry Merlo conceded during the earnings call that day.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.